Cargando…

Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention

OBJECT: To identify the expression levels of ECT2 (epithelial cell transforming sequence 2) in triple-negative breast cancer (TNBC) before and after administration of paclitaxel (PTX) and explore the interaction between ECT2 and PTX in breast cancer treatment. METHODS: Lentiviral (LV) packaging ECT2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hongkun, Liu, Honggang, Li, Jun, Wei, Shuanyu, Liu, Xiaojun, Wan, Huili, Zheng, Peiming, Zheng, Huixia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756022/ https://www.ncbi.nlm.nih.gov/pubmed/33376345 http://dx.doi.org/10.2147/OTT.S275725

Ejemplares similares

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer
por: Daulat, Avais M., et al.
Publicado: (2019)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine
por: Yang, Fan, et al.
Publicado: (2023)

Self-Assembly Engineering Nanodrugs Composed of Paclitaxel and Curcumin for the Combined Treatment of Triple Negative Breast Cancer
por: Zuo, Shuting, et al.
Publicado: (2021)

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
por: Qi, Yanfeng, et al.
Publicado: (2012)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye, Jun, et al.
Publicado: (2016)

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer
por: Liu, Xi-Yu, et al.
Publicado: (2020)

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
por: Blanchard, Zannel, et al.
Publicado: (2015)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple‐negative breast cancer
por: Yang, Na, et al.
Publicado: (2019)

Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment
por: Chen, Tianyu, et al.
Publicado: (2022)

Molecular Imaging of Oxygenation Changes during Immunotherapy in Combination with Paclitaxel in Triple Negative Breast Cancer
por: Napier, Tiara S., et al.
Publicado: (2023)

Does ECT Work? the Impact of ECT on Depression
por: Collins, Dawn
Publicado: (2023)

Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer
por: Zheng, Yi-Zi, et al.
Publicado: (2022)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Immunotherapeutic interventions of Triple Negative Breast Cancer
por: Li, Zehuan, et al.
Publicado: (2018)

Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer
por: Lian, Bi, et al.
Publicado: (2020)

Investigating the Heterogeneity of Immune Cells in Triple-Negative Breast Cancer at the Single-Cell Level before and after Paclitaxel Chemotherapy
por: Zhao, Heng, et al.
Publicado: (2023)

THE PRACTICE OF ECT IN INDIA: II. THE PRACTICAL ADMINISTRATION OF ECT
por: Andrade, Chittaranjan, et al.
Publicado: (1993)

ECT-Resistant Bipolar Depression Treated with a Single Course of Triple Chronotherapy
por: Webb, Jadon
Publicado: (2022)

HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
por: Lyu, Hui, et al.
Publicado: (2023)

Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
por: Reeder, A, et al.
Publicado: (2015)

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer
por: Schmid, Peter
Publicado: (2018)

Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA
por: Zhang, Qian, et al.
Publicado: (2020)

TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel
por: Wardhani, Bantari WK, et al.
Publicado: (2020)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
por: Pederson, Petra J., et al.
Publicado: (2021)

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
por: Emens, Leisha A, et al.
Publicado: (2021)

ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models
por: Polonio‐Alcalá, Emma, et al.
Publicado: (2022)

Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer
por: Jin, Xin, et al.
Publicado: (2020)

REEVALUATION OF ECT
por: Abhyankar, Ravi
Publicado: (1985)

ECT Transport
por: Serge Pelletier, et al.
Publicado: (2007)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Effectiveness of Bifrontal ECT in Practice: A Comparison with Bitemporal ECT
por: Viswanath, Biju, et al.
Publicado: (2011)

THE PRACTICE OF ECT IN INDIA : ISSUES RELATING YO THE ADMINISTRATION OF ECT
por: Agarwal, A.K., et al.
Publicado: (1992)

SEIZURE DURATION OVER ECT SESSIONS: INFLUENCE OF SPACING ECTS
por: Janakiramaiah, N., et al.
Publicado: (1992)

A review of ketamine’s role in ECT and non-ECT settings
por: Jankauskas, Vytautas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bslcg8kmuvi72f4m80524qu14j